A vision that defines our future.
Daiichi Sankyo, Inc. (DSI) is a member of the Daiichi Sankyo Group which spans 54 countries and includes an international network of affiliates focused on the global and regional commercialization of our pharmaceutical products. The organization, which includes U.S. commercial operations, also includes global clinical development – Daiichi Sankyo Pharma Development (DSPD).
Our pursuit of new medicines is fueled by the relentless scientific curiosity of our employees, a willingness to examine new ideas and the pairing of existing information with novel concepts. We innovate by creating new medicines, as well as new methods of drug discovery and delivery.
Headquartered in Edison, NJ, DSPD is responsible for overseeing all global clinical trials of our pipeline drug compounds, with the exclusion of trials conducted in Japan. DSPD is the product development arm of the U.S. organization, engaged in Clinical Development, Translational Medicine & Clinical Pharmacology, Regulatory Affairs & Risk Management, Informatics & Knowledge Management, Biostatistics and Data Operations and Development Research. In addition to conducting clinical studies, we expedite product registrations for the United States and Europe, and collaborate with our Tokyo parent company on all of our global product development projects as well.
Innovation is integral to the mission that drives us today, and to the vision that defines our future.